

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)



(10) International Publication Number
WO 2023/212341 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 48/00 (2003.01)
A61K 9/51 (2006.01) C12N 15/864 (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2023/020435

(22) International Filing Date:

28 April 2023 (28.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/336,754 29 April 2022 (29.04.2022) US
63/343,797 19 May 2022 (19.05.2022) US

(71) Applicant: **COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC.** [US/US]; 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US).

(72) Inventors: **PUISIS, John**; c/o Cour Pharmaceuticals Development Company Inc., 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US). **ELHOFY, Adam**; c/o Cour Pharmaceuticals Development Company Inc., 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US). **PODOJIL, Joseph**; c/o Cour Pharmaceuticals Development Company Inc., 8045

Lamon Avenue, #1202, Skokie, IL 60077 (US). **BOYNE, Michael**; c/o Cour Pharmaceuticals Development Company Inc., 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US). **MURTHY, Tushar**; c/o Cour Pharmaceuticals Development Company Inc., 8045 Lamon Avenue, #1202, Skokie, IL 60077 (US).


(74) Agent: **NEVILLE, Katherine, L.**; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: TOLERIZING IMMUNE MODIFYING NANOPARTICLES FOR OVERCOMING THE IMMUNOGENICITY OF THERAPEUTIC VECTORS AND PROTEINS

Figure 1



(57) Abstract: The present application is directed, in general, to tolerizing immune mediated particles comprising gene therapy vector antigens for use in combination with gene therapy regimens in order to reduce immunogenicity to the gene therapy vector antigens and/or transgene protein products expressed by the vectors.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*